Inquiry proposes improved tax incentives for R&D in Sweden

20 January 2025

A Swedish government inquiry is proposing changed tax rules to give business research and development better conditions.

With simpler rules for R&D deductions and a reformed expert tax, it is hoped that Sweden will become more attractive to both investment and international expertise, says the Swedish pharma trade group, Lif, noting that this will stimulate Swedish growth.

The inquiry into tax rules that benefit R&D has now presented its review of the R&D deduction and expert tax rules. Its proposals are intended to make it easier and more advantageous for companies to conduct R&D in Sweden and recruit international key competence. Innovation is an important part of the Swedish economy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical